Neutralizing antibody assay for a fully human PD-1 blocking monoclonal antibody
Learn how Syngene’s PD-1 neutralizing antibody bioassay reduced donor variability and drug interference for immunogenicity assessment. Read the full case study today.
Reimagining CROs: Integrated Innovation Partnerships as the Future of Drug Discovery
Eroom’s Law highlights a troubling trend in pharmaceutical R&D: the cost and time required to develop new drugs have been steadily increasing despite technological advances (1). As a result, drug discovery is under constant pressure.
Immunogenicity assay for an RNAi therapeutic (small interfering RNA) on the MSD platform
Syngene’s MSD-based ADA assay enabled sensitive, drug-tolerant immunogenicity assessment for a clinical siRNA therapeutic in regulated studies. Learn more.